From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook Post published:July 7, 2025 Post category:Interviews/Pα+
Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics Post published:July 3, 2025 Post category:Interviews
Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans Post published:July 1, 2025 Post category:Interviews/Pα+
Psychedelics in Japan: Dr. Hiroyuki Uchida on Studies, Stigma, and the Road Ahead Post published:May 21, 2025 Post category:Interviews
Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and Psychiatry’s, Wild Ride Post published:April 18, 2025 Post category:Interviews/Pα+
The VA, Psychedelics, and the Future of Mental Health: A Conversation with Shereef Elnahal, Former VA Under Secretary for Health Post published:April 14, 2025 Post category:Interviews
Behind the Bill: Inside a Bipartisan Effort to Bring Psychedelic Therapy to Veterans Post published:April 4, 2025 Post category:Interviews
Inside the World’s Most Active Psychedelic Therapy Site: A Conversation with Sunstone Therapies Post published:March 12, 2025 Post category:Interviews/Pα+
Forging a Path to Access: Congressmen Correa and Bergman on the Future of Psychedelics in the U.S. Post published:March 4, 2025 Post category:Interviews
MDMA for Active-Duty Troops: Aaron Wolfgang on DoD’s Unprecedented Study Post published:February 19, 2025 Post category:Interviews/Pα+